Multicenter, open label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD) - the DETECT Trial

AETERNA ZENTARIS GMBH0 sites100 target enrollmentAugust 30, 2021

Overview

No summary available.

Registry

who.int

Start Date

August 30, 2021

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Subjects are eligible to be included in the trial only if all of the following criteria apply:
•1\. Informed consent of subject, parent(s) or legally acceptable representative (LAR) of subject and child assent, if appropriate, must be obtained before any trial\-related activities. Trial\-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
•2\. Male and female pediatric subjects from 2 to less than 18 years of age at the time of signing informed consent.
•\- A minimum body weight of 10 kg for a subject is to be respected, to ensure the safety of blood sampling procedures due to the blood volumes required to be taken.
•3\. Indication for the performance of growth hormone stimulation test.
•4\. Presence of a height measurement minimum 6 and maximum 18 months prior to screening.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) no
•F.1\.2\.1 Number of subjects for this age range

•Subjects are excluded from the trial if any of the following criteria apply:
•Lack of suitability for the trial:
•1\. Established diagnosis of a disease that is sufficient to explain growth deficiency or metabolic disorders that are also associated with short stature (e.g., Turner syndrome, skeletal dysplasia's, celiac disease, etc.).
•2\. Ongoing growth hormone therapy.
•3\. Presence of hypothyroidism and/or adrenal insufficiency without adequate and stable replacement therapy treatment for at least 30 days prior to first GHST.
•4\. Treatment with drugs directly affecting the pituitary secretion of somatotropin (e.g., somatostatin analogues, clonidine, levodopa and dopamine agonists) or provoking the release of somatostatin (antimuscarinic agents e.g., atropine).
•5\. Medical history of ongoing clinically symptomatic psychiatric disorders.
•6\. 2nd or 3rd degree atrioventricular\-block, prolongation of the QRS complex over 120 milliseconds, prolongation of the QTc interval over 450milliseconds, or any other clinically significant abnormal electrocardiogram results at the V2 pre\-dose ECG as judged by the investigator.
•7\. Previous participation in this trial. Participation is defined as signed informed consent.
•8\. Participation in any clinical trial of an approved or non\-approved investigational medicinal product within 30 days before screening.